Does aspirin reduce the benefit of an angiotensin-converting enzyme inhibitor? Choosing between the Scylla of observational studies and the Charybdis of subgroup analysis

Circulation. 2006 Jun 6;113(22):2566-8. doi: 10.1161/CIRCULATIONAHA.106.629212.
No abstract available

Publication types

  • Comment
  • Editorial

MeSH terms

  • Angiotensin-Converting Enzyme Inhibitors / pharmacology
  • Angiotensin-Converting Enzyme Inhibitors / therapeutic use*
  • Anti-Inflammatory Agents, Non-Steroidal / adverse effects*
  • Anti-Inflammatory Agents, Non-Steroidal / pharmacology
  • Aspirin / adverse effects*
  • Aspirin / pharmacology
  • Cohort Studies
  • Dose-Response Relationship, Drug
  • Drug Interactions
  • Drug Therapy, Combination
  • Enzyme Inhibitors / pharmacology
  • Enzyme Inhibitors / therapeutic use
  • Heart Diseases / classification
  • Heart Diseases / drug therapy*
  • Heart Diseases / physiopathology
  • Hemodynamics / drug effects
  • Humans
  • Multivariate Analysis
  • Reproducibility of Results
  • Time Factors

Substances

  • Angiotensin-Converting Enzyme Inhibitors
  • Anti-Inflammatory Agents, Non-Steroidal
  • Enzyme Inhibitors
  • Aspirin